Adverts

Open Access Articles- Top Results for Seproxetine

Seproxetine

</th></tr></th></tr>
Seproxetine
File:Norfluoxetine2DACS.svg
Systematic (IUPAC) name
(S)-3-Phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
Clinical data
  • Uncontrolled
Oral
Pharmacokinetic data
Half-life 4-16 days
Identifiers
126924-38-7
None
PubChem CID 4541
IUPHAR ligand 208
DrugBank DB06731
ChemSpider 4382
UNII 25CO3X0R31 7pxY
Chemical data
Formula C16H16F3NO
295.30 g/mol

Seproxetine, also known as (S)-norfluoxetine, is a selective serotonin reuptake inhibitor (SSRI). It is the most important active metabolite of the widely used antidepressant fluoxetine, but little is known about its pharmacological actions. At least one additional pharmacological target of Seproxetine has been identified, the GABAa receptor, where it acts as a positive allosteric modulator with a high potency which makes this mechanism a likely factor of fluoxetine's observed superiority as an anxiolytic agent compared to other antidepressants with clinically equivalent serotonin reuptake inhibition. Seproxetine was being investigated by Eli Lilly and Company as an antidepressant; however, a cardiac side effect was noted and development was discontinued. The use of seproxetine was banned in Spain in 1998 after a study linked it to kidney damage.[citation needed]

Synthesis

Seproxetine can be synthesized from a protected 3-amino-1-phenylpropan-1-ol and 1-fluoro-4-trifluoromethyl(benzene):

File:Seproxetine.png
Seproxetine synthesis: Fuller, R. W.; Robertson, D. W.; Wong, D. T.; European Patent, 1990, EP 0369685 

References

Lua error in package.lua at line 80: module 'Module:Buffer' not found.